How we exploit the low pH elution condition from Protein A chromatography to inactivate enveloped viruses while protecting the antibody.
Welcome back to our deep‑dive series on monoclonal antibody manufacturing. In Step 5, we eluted the monoclonal antibody from the Protein A column at low pH (typically 3.2–3.6). This eluate is concentrated, partially purified, and – crucially – already at the perfect condition for the next step: Low pH Viral Inactivation.
Viral safety is non‑negotiable for biologic products derived from mammalian cell lines (CHO cells). Regulatory agencies (FDA, EMA, ICH Q5A) require at least two orthogonal viral clearance steps in the downstream process. Low pH inactivation is one of the most robust and widely used steps, specifically targeting enveloped viruses (e.g., murine leukemia virus, pseudorabies virus, xenotropic murine leukemia virus).
In this post, we will cover the science, the step‑by‑step procedure, critical parameters, validation requirements, and common pitfalls.
Overview: What Is Low pH Viral Inactivation?
Principle: Enveloped viruses have a lipid membrane surrounding their protein capsid. At low pH (typically ≤3.8), the lipid envelope undergoes irreversible fusion, rearrangement, or disruption, rendering the virus non‑infectious. The antibody, meanwhile, is designed to be stable at low pH for a limited time.
Why perform this step immediately after Protein A?
The Protein A eluate is already at pH 3.2–3.6 – no need for an extra acid addition step.
The mAb concentration is high (5–50 g/L), which can protect against aggregation.
Impurity levels (HCPs, DNA) are low, reducing the risk of precipitate formation.
Regulatory expectation: Demonstrate a log reduction value (LRV) of ≥4 log₁₀ (99.99%) for model enveloped viruses (e.g., X‑MuLV) during process validation.
Step 6.1: Step Design – From Elution to Inactivation Hold
In a typical manufacturing process, the Protein A eluate is collected directly into a vessel containing neutralization buffer (e.g., 1 M Tris, pH 8.5–9.0) to raise the pH to 5.0–6.0 for stability. For viral inactivation, we delay neutralization and hold the eluate at low pH for a defined period.
Two common approaches:
| Approach | Description | Pros | Cons |
|---|---|---|---|
| In‑line acidification | Adjust eluate to target pH (e.g., 3.5) using a second pump and static mixer before the hold vessel | Precise control; continuous processing possible | Requires additional equipment; risk of local over‑acidification |
| Batch hold after elution | Collect eluate at elution pH (already 3.2–3.6); adjust if needed; hold in vessel | Simpler; fewer pumps | pH may drift; less uniform mixing |
For legacy mAb processes (like Humira), the batch hold approach is common because the Protein A elution pH is already within the inactivation range.
Step 6.2: Step‑by‑Step Procedure
Step 6.2.1: Verify Elution pH
Immediately after elution, measure the pH of the pooled eluate (or in‑line). It should be 3.2–3.6. If it is higher (e.g., >3.8 due to buffer carryover), titrate down with 0.5–1.0 M citric acid or acetic acid.
Step 6.2.2: Low pH Hold
Target pH: 3.4–3.6 (typically 3.5 ± 0.1). Lower pH (e.g., 3.0) gives faster inactivation but increases aggregation risk.
Temperature: Usually 15–25°C (room temperature) or 2–8°C. Cold temperature slows inactivation kinetics; room temperature is preferred for faster log reduction.
Hold time: 30–120 minutes. Industry standard is 60 minutes at 3.5–3.6 and 18–25°C.
Agitation: Gentle stirring or no agitation (static hold). Over‑mixing can introduce air bubbles and cause surface denaturation.
Step 6.2.3: Neutralization
After the hold, raise the pH to 5.0–6.0 (or to the pH required for the next chromatography step, typically 5.5–6.0 for cation exchange). Use a sterile, concentrated base such as:
1 M Tris base (pH not adjusted – add slowly)
1–2 M sodium hydroxide (NaOH)
1 M arginine (may help stabilize)
Neutralization method: Add base gradually while mixing. The pH change should be smooth; avoid local pH spikes >8.0, which can cause aggregation.
Step 6.2.4: Hold Before Next Step
The neutralized pool (now called Viral Inactivated Pool or Low pH Hold Pool) can be held at 2–8°C for up to 24–48 hours before the next chromatography step (polishing).
Testing after inactivation:
pH (confirm 5.0–6.0)
Turbidity (should be low; any precipitate indicates mAb instability)
Bioburden (if held >24 hours)
Optionally, a rapid ELISA for HCPs or DNA (though this is usually done at later steps)
Step 6.3: Critical Process Parameters (CPPs)
| Parameter | Typical Range | Impact on Viral Inactivation | Impact on Product Quality |
|---|---|---|---|
| pH | 3.4–3.8 | Lower pH → faster inactivation (≥4 log in 30 min) | Lower pH → higher aggregation risk |
| Temperature | 15–25°C | Higher temperature → faster inactivation | Higher temperature → more aggregation and deamidation |
| Hold time | 30–120 min | Longer time → higher LRV (plateaus after ~60 min) | Longer time → increased aggregation and fragmentation |
| mAb concentration | 5–50 g/L | Minimal direct effect on viral inactivation | Higher concentration → more prone to aggregation |
| Buffer composition | Citrate, acetate, or glycine | Citrate may have mild synergistic effect | Some buffers (e.g., histidine) protect against aggregation |
Design space concept: Many manufacturers validate a range (e.g., pH 3.3–3.8, time 45–120 min, temp 15–30°C) to allow operational flexibility.
Step 6.4: Equipment and Facility Considerations
Equipment needed:
| Component | Specification |
|---|---|
| Hold vessel | Stainless steel or single‑use bag (e.g., Thermo HyPerforma, Sartorius Flexsafe) with jacket for temperature control; volume 500–5,000 L |
| Mixing system | Magnetic or top‑mounted impeller (low shear); or rocking platform for single‑use bags |
| pH probe | In‑situ sterilizable (e.g., Mettler Toledo, Hamilton); calibrated before each campaign |
| Base addition system | Peristaltic or diaphragm pump with sterile tubing; base reservoir (e.g., 50–200 L bag) |
| Acid addition system (if needed) | Similar, with 0.5–1.0 M citric or acetic acid |
| Temperature control | Chilled water or glycol jacket; or incubator for single‑use bags (e.g., Cytiva ReadyToProcess) |
| Sampling ports | Aseptic sampling devices (e.g., Sartorius NovaSeptum, Merck PureSMA) |
Facility design:
The low pH hold step is usually performed in the same room as Protein A chromatography (post‑column area).
The vessel should be vented through a 0.22 µm hydrophobic filter to maintain sterility.
For potent or high‑risk products, the room may need containment (the virus being inactivated is non‑infectious after the hold, but the starting pool is considered potentially infectious).
Step 6.5: Viral Inactivation Validation (Regulatory Requirements)
Before licensure, you must demonstrate that the low pH step achieves ≥4 log₁₀ reduction of relevant model enveloped viruses.
Typical validation study design (scale‑down model):
Select model viruses:
X‑MuLV (xenotropic murine leukemia virus) – standard model for retrovirus‑like particles from CHO cells.
PRV (pseudorabies virus) – herpesvirus, more resistant to low pH.
Reovirus (non‑enveloped) – negative control (low pH should NOT inactivate non‑enveloped viruses; that’s the role of other steps).
Spike the virus into Protein A eluate (at scaled‑down volume, e.g., 100 mL).
Adjust to target pH (e.g., 3.5) and hold for defined time (e.g., 60 min) at defined temperature (e.g., 22°C).
Take samples at time zero, 15, 30, 60, 90, 120 minutes and immediately neutralize to pH 5.5.
Quantify infectivity (plaque assay or TCID₅₀) on permissive cell lines.
Calculate LRV = log₁₀(virus input) – log₁₀(virus output after inactivation).
Acceptance criteria (typical):
≥4 log reduction for X‑MuLV and PRV
No significant reduction for non‑enveloped virus (reovirus) – proves specificity of low pH for enveloped viruses
Important: The validation must use worst‑case conditions within the operating range (e.g., highest pH, lowest temperature, shortest hold time) to ensure robustness.
Step 6.6: Impact on Product Quality – Managing Aggregation Risk
Low pH is stressful for mAbs. The most common product quality issue is aggregation (soluble or insoluble). Even 1–2% increase in high molecular weight species can affect safety (immunogenicity) and efficacy.
Mitigation strategies:
| Strategy | How it works |
|---|---|
| Optimize pH | Use the highest pH that still achieves ≥4 log reduction (e.g., 3.6–3.7 instead of 3.4) |
| Reduce hold time | Validate the minimum time needed (e.g., 30 min instead of 60 min) |
| Lower temperature | Hold at 2–8°C instead of room temperature (but validate LRV – kinetics are slower) |
| Add excipients | Sucrose (0.5–1 M), trehalose, arginine, or polysorbate 80 in the elution buffer or post‑elution |
| Rapid neutralization | Minimize the time at low pH; use in‑line neutralization with a static mixer |
| High concentration protection | At higher mAb concentrations (>20 g/L), molecules crowd and may aggregate more – test both low and high concentration |
Monitoring: After neutralization, run SEC‑HPLC (size exclusion chromatography) to quantify aggregates. A well‑designed low pH step should cause <1% absolute increase in aggregates.
Step 6.7: What Can Go Wrong? (Troubleshooting)
| Problem | Possible Cause | Remedy |
|---|---|---|
| Insufficient viral reduction (LRV <4 log) | pH too high (≥3.8); temperature too low; hold time too short | Lower pH (to 3.4); increase temperature to 25°C; extend hold to 90 min |
| High aggregation (>5% increase) | pH too low (≤3.2); hold time too long; temperature too high; no excipients | Raise pH to 3.6–3.7; shorten hold to 30 min; add 0.5 M sucrose |
| Precipitation (turbidity) | mAb unstable at low pH; high concentration; salt effects | Dilute before low pH hold; change buffer (e.g., citrate vs. acetate); add arginine |
| pH drift during hold | CO₂ absorption from air; insufficient buffering | Use sealed vessel with vent filter; increase buffer concentration (e.g., 50 mM citrate) |
| Incomplete neutralization | Base added too quickly; poor mixing | Add base slowly with continuous mixing; use in‑line static mixer |
| Low recovery after neutralization | Aggregates removed by filtration; precipitation on vessel walls | Filter before measurement; optimize conditions to avoid precipitation |
Step 6.8: Alternatives and Emerging Approaches
While low pH inactivation is the gold standard for mAbs, alternatives exist:
| Method | When used |
|---|---|
| Detergent inactivation (e.g., Triton X‑100, TNBP) | For products unstable at low pH (e.g., some Fc‑fusion proteins, IgM) |
| Heat inactivation (pasteurization) | For plasma‑derived products; less common for mAbs |
| UV‑C irradiation | Continuous processes; still emerging for mAbs |
| High pH inactivation (e.g., pH 11–12) | Rare; risks deamidation and fragmentation |
For a standard IgG1 mAb like Humira, low pH remains the simplest, most robust, and regulatory‑preferred method.
What Comes Next?
The viral inactivated pool, now at neutral pH (5.0–6.0), is ready for the polishing chromatography steps that remove residual impurities (HCPs, DNA, leached Protein A, aggregates, and viruses). The first of these is typically Cation Exchange Chromatography (CEX) , which will be covered in Step 7.
Questions for our readers:
What low pH hold conditions (pH, time, temperature) do you use for your IgG1 mAb?
Have you experienced aggregation during low pH inactivation? How did you solve it?
Share your experiences below. Next week: Step 7 – Cation Exchange Chromatography for polishing.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
